Key Highlights
- Vetter moves Development Services site from Skokie to Des Plaines, IL.
- Major investment in commercial production site in Saarland, Germany.
- New buildings and expansion will double U.S. capacity.
- Expected creation of up to 2,000 new jobs in Germany by 2030.
Source: Business Wire
Notable Quotes
- “As an independent and family-owned company, we prioritize thoughtful and strategic planning to support our long-term business growth,” — Senator h.c. Udo J. Vetter, Chairman of the Advisory Board at Vetter Pharma International GmbH
- “After careful consideration, Germany, and Saarland in particular, prove to be the location with the best-fitting conditions for expanding our commercial operations,” — Thomas Otto, Managing Director at Vetter Pharma International GmbH
- “We know that the multiannual-long investments at our Ravensburg and Langenargen sites will contribute to this, however the market and our customers are in need of even more capacity. We are proud to announce further investments in Des Plaines, IL, USA, and Germany,” — Peter Soelkner, Managing Director at Vetter Pharma International GmbH
SoHC's Take
Vetter’s strategic move to expand its operations in both the U.S. and Germany is a robust response to the increasing outsourcing demand in the injectable drug industry. By relocating and expanding their U.S. Development Services and investing heavily in a new commercial production site in Saarland, Germany, Vetter is positioning itself to better serve its global clientele. These expansions not only double the U.S. capacity but also leverage Vetter’s extensive experience in Germany, ensuring efficiency and predictability in project execution. With the creation of up to 2,000 new jobs in Germany, Vetter is not only contributing to the local economy but also ensuring the availability of life-saving medications worldwide. This forward-thinking approach underlines Vetter’s commitment to quality, sustainability, and long-term growth.
